JMJD1C-AS1: A Promising Drug Target and Biomarker for the Treatment of Cancer

Target Name: JMJD1C-AS1

NCBI ID: G84989

JMJD1C-AS1

Other Name(s): JMJD1C antisense RNA 1

JMJD1C-AS1: A Promising Drug Target and Biomarker for the Treatment of Cancer

Cancer is one of the leading causes of morbidity and mortality worldwide, with over 40% of the global cancer burden affecting the immune-system. The development of new treatments and their subsequent approval by regulatory authorities is crucial in the fight against cancer. One promising approach to cancer treatment is the use of small molecules, such as JMJD1C-AS1, which can inhibit the activity of JMJD1C, an enzyme involved in the production of the metabolite As1.

JMJD1C and its Metabolite As1

JMJD1C (Jumon), also known as human sphingomyelinase D1 (HSMD1), is an enzyme that

Protein Name: JMJD1C Antisense RNA 1

The "JMJD1C-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about JMJD1C-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets